Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ONVO - Organovo Holdings Inc


Previous close
0.6013
0   0%

Share volume: 20,696
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.60
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 8%
Dept financing 1%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-6.27%
1 Month
2.65%
3 Months
-40.68%
6 Months
-42.57%
1 Year
-52.85%
2 Year
-74.89%
Key data
Stock price
$0.60
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.50 - $2.05
52 WEEK CHANGE
-$0.48
MARKET CAP 
8.336 M
YIELD 
N/A
SHARES OUTSTANDING 
14.373 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.71
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$38,425
AVERAGE 30 VOLUME 
$52,606
Company detail
CEO:
Region: US
Website: organovo.com
Employees: 43
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

organovo (nyse mkt: onvo) designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. the company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. these 3d human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. in addition to numerous scientific publications, their technology has been featured in the wall street journal, time magazine, the economist, and other outlets. organovo is changing the shape of medical research and practice.

Recent news